Test Price
2,800 AEDโ Home Collection Available
TECTA Gene Autosomal Dominant Deafness Type 12 (DFNA12) Genetic Test in Dubai & UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity and specificity via ISO 15189:2022 accredited NGS platform.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM โ 11 PM).
Clinical Guidance: Comprehensive pre- and post-test genetic counseling by a board-certified Consultant Medical Geneticist.
Direct Billing: Insurance verification and direct billing support via WhatsApp at
+971545488731
Test Overview & Methodology
The TECTA gene encodes tectorin-alpha, a critical protein for the structural integrity of the cochlear tectorial membrane. Pathogenic variants in this gene lead to autosomal dominant non-syndromic hearing loss (DFNA12). This targeted Next-Generation Sequencing (NGS) panel provides complete exon coverage of the TECTA gene, delivering a definitive molecular diagnosis to guide clinical management, prognostic counseling, and family cascade screening.
| Feature | Our Advanced NGS Panel | Standard Clinical Evaluation |
|---|---|---|
| Precision | >99.9% analytical sensitivity & specificity | Pure-tone audiometry alone โ genetic aetiology undetermined |
| Method | Full exon NGS (LC-MS/MS verified) | Audiometry / subjective family history |
| Turnaround | 21 โ 28 Business Days | Not applicable (no molecular data) |
| Clinical Outcome | Mutationโguided counselling, cochlear implant candidacy | Symptom management only |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I understand the profound impact of hereditary hearing loss on families. The TECTA NGS test provides a definitive molecular answer, enabling precise prognostic counseling and targeted rehabilitation strategies. It is imperative that this genomic data is interpreted within the context of a complete audiological evaluation and a three-generation family pedigree. I strongly advocate for structured pre- and post-test genetic counseling to empower patients with actionable knowledge."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory: Medication & Therapy Continuation
โ ๏ธ Important: This genetic test is a diagnostic tool and does not replace your current clinical care. Do not discontinue any prescribed medications, hearing aids, or other therapies without direct consultation with your treating physician. Always correlate genomic results with clinical presentation.
Patient Safety & Exclusion Criteria
- Exclusion Criteria: This test is not suitable for individuals with sudden sensorineural hearing loss without a clear family history, active middle ear infections, or a prior diagnosis of syndromic hearing loss without genetic confirmation.
- Red Flags (Seek Immediate Medical Attention): Acute onset vertigo, rapidly progressive hearing loss over hours to days, facial nerve weakness, or new neurological deficits require immediate clinical evaluation, not genetic testing.
- Informed Consent: A dedicated genetic counseling session is required before sample collection to obtain informed consent, in full compliance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the TECTA Gene NGS Test and who should consider it?
The TECTA NGS test is a targeted genetic analysis designed to identify pathogenic variants in the TECTA gene, which is a primary cause of autosomal dominant non-syndromic hearing loss (DFNA12). It is clinically indicated for children and adults presenting with early-onset, bilateral sensorineural hearing loss who have at least one first-degree relative with a confirmed hearing impairment. The test provides a definitive molecular diagnosis, facilitates accurate prognostic assessments, and informs reproductive planning.
2. How is the sample collected and is home collection available?
A standard peripheral blood draw (3-5 mL into an EDTA tube) is sufficient for high-quality DNA extraction. Our DHA-licensed healthcare professionals provide a VIP Mobile Phlebotomy service, visiting your home, office, or hotel between 8 AM and 11 PM. The procedure is quick (under 10 minutes) and minimally invasive. Samples are transported under strict temperature-controlled cold-chain conditions to our ISO-accredited laboratory in Dubai Healthcare City. No fasting or alteration to your medication schedule is required.
3. What do my results mean, and what are the next steps?
Your comprehensive molecular report will be reviewed and signed off by our Consultant Medical Geneticist. A positive result confirming a pathogenic TECTA mutation allows for targeted hearing rehabilitation strategies, including optimized hearing aid fitting or cochlear implant candidacy evaluation. Our clinical team will coordinate a structured post-test genetic counseling session to explain the implications for you and your family, including cascade testing options for at-risk relatives. If the result is negative or equivocal, our geneticist may recommend broader panel testing or whole exome sequencing to investigate other potential genetic etiologies.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the highest standards of data security and regulatory compliance. Your genetic data is handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The laboratory holds a valid DHA Facility License (Number: 1143) and is located at Premises 105, Floor 1, Building 33, Dubai Healthcare City. All test results are delivered with full confidentiality and processed using de-identified data protocols.
Clinical & Logistical Metadata
| Test Name | TECTA Gene (DFNA12) NGS Analysis |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21 โ 28 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA, 3-5 mL) |
| Methodology Used | Next-Generation Sequencing (NGS) โ Full Gene Exon Coverage |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 83397-6 |
| DHA Facility License & Address | DNA Labs UAE | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians